公开(公告)号：US12060380B2

公开(公告)日：2024-08-13

申请号：US17257917

申请日：2019-07-05

申请人： KANCERA AB

发明人： Jan Vågberg ,  Styrbjörn Byström ,  Elisabeth Olsson ,  Mattias Jönsson

IPC分类号： C07F9/6561 ,  A61K9/08 ,  A61K31/685 ,  A61K31/70 ,  A61K45/06

CPC分类号： C07F9/6561 ,  A61K9/08 ,  A61K31/685 ,  A61K31/70 ,  A61K45/06

摘要： There is provided a compound of formula (I), wherein R1, R2, Q1 and formula (X) are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

公开(公告)号：US20230068240A1

公开(公告)日：2023-03-02

申请号：US17966294

申请日：2022-10-14

申请人： KANCERA AB

发明人： Jan Vågberg ,  Styrbjörn Byström

IPC分类号： C07D513/04 ,  C07D239/56

摘要： Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.

公开(公告)号：US11542281B2

公开(公告)日：2023-01-03

申请号：US17055172

申请日：2019-05-15

申请人： KANCERA AB

发明人： Jan Vågberg ,  Styrbjörn Byström

IPC分类号： C07D239/56 ,  C07D513/04

摘要： Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.

公开(公告)号：US20210188873A1

公开(公告)日：2021-06-24

申请号：US17055172

申请日：2019-05-15

申请人： KANCERA AB

发明人： Jan Vågberg ,  Styrbjörn Byström

IPC分类号： C07D513/04 ,  C07D239/56

摘要： Described herein is a process for the preparation of a compound of Formula I, wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.

公开(公告)号：US11691988B2

公开(公告)日：2023-07-04

申请号：US17966294

申请日：2022-10-14

申请人： KANCERA AB

发明人： Jan Vågberg ,  Styrbjörn Byström

IPC分类号： C07D513/04 ,  C07D239/56

CPC分类号： C07D513/04 ,  C07D239/56

摘要： Described herein is a process for the preparation of a compound of Formula I,




wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.

公开(公告)号：US11339183B2

公开(公告)日：2022-05-24

申请号：US17372125

申请日：2021-07-09

申请人： KANCERA AB

发明人： Jan Vågberg ,  Styrbjörn Byström ,  Elisabeth Olsson ,  Mattias Jönsson

IPC分类号： C07F9/6561 ,  A61K9/08 ,  A61K31/685 ,  A61K31/70 ,  A61K45/06

摘要： There is provided a compound of formula I, wherein R1, R2, Q1 and are as defined herein, which compounds are useful in the treatment of diseases and disorders associated with elevated levels of CX3CR1 and/or CX3CL1, in particular acute and/or chronic inflammation, eye diseases, lung diseases, skin diseases, joint and/or bone diseases, autoimmune diseases, cardiovascular diseases, metabolic diseases, brain diseases, neurodegenerative diseases, pain, cancer, liver diseases, kidney diseases, gastrointestinal diseases, human immunodeficiency virus and mood disorders.

公开(公告)号：US20230322807A1

公开(公告)日：2023-10-12

申请号：US18199899

申请日：2023-05-19

申请人： KANCERA AB

发明人： Jan Vågberg ,  Styrbjörn Byström

IPC分类号： C07D513/04 ,  C07D239/56

CPC分类号： C07D513/04 ,  C07D239/56

摘要： Described herein is a process for the preparation of a compound of Formula I,




wherein R1 and R2 each have the meanings provided in the description. Also described is a process for the preparation of pharmaceutically-active compounds including the process for the preparation of compounds of Formula I.

公开(公告)号：US11660303B2

公开(公告)日：2023-05-30

申请号：US17245195

申请日：2021-04-30

申请人： KANCERA AB

发明人： Håkan Mellstedt ,  Styrbjörn Byström ,  Jan Vågberg ,  Elisabeth Olsson

IPC分类号： A61K31/551 ,  A61K31/496 ,  A61K31/506 ,  A61K31/497 ,  A61K31/5377

CPC分类号： A61K31/551 ,  A61K31/496 ,  A61K31/497 ,  A61K31/506 ,  A61K31/5377

摘要： A compound of formula (I′) or (I″)




or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.

公开(公告)号：US11008318B2

公开(公告)日：2021-05-18

申请号：US16314708

申请日：2017-07-10

申请人： KANCERA AB

发明人： Håkan Mellstedt ,  Styrbjörn Byström ,  Jan Vågberg ,  Elisabeth Olsson

IPC分类号： C07D471/04 ,  A61P25/28

摘要： Compound of formula (I′) or (I″) or a pharmaceutically acceptable salt thereof. The compound is an inhibitor of mammalian kinase enzyme activity, including ROR1 tyrosine kinase activity and may be used in the treatment of disorders associated with such activity.